Protective Effects of Monosialoganglioside on Oxaliplatin-induced Chronic Sensory Neurotoxicity

CAO Mengran; HUA Haiqing; QIN Shukui

doi:10.3971/j.issn.1000-8578.2014.04.023

Cancer Research on Prevention and Treatment > 2014 > 41(04): 387-390. > DOI: 10.3971/j.issn.1000-8578.2014.04.023

CAO Mengran, HUA Haiqing, QIN Shukui. Protective Effects of Monosialoganglioside on Oxaliplatin-induced Chronic Sensory Neurotoxicity[J]. Cancer Research on Prevention and Treatment, 2014, 41(04): 387-390. DOI: 10.3971/j.issn.1000-8578.2014.04.023

Citation:

PDF (1064 KB)

Protective Effects of Monosialoganglioside on Oxaliplatin-induced Chronic Sensory Neurotoxicity

Department of Medical Oncology??Cancer Center of PLA,81 Hospital of PLA,Nanjing210002, China

More Information

Received Date: December 26, 2012
Revised Date: April 09, 2013

Graphical Abstract

Abstract

Abstract

Objective To observe the protective effects of monosialoganglioside on oxaliplatin-induced sensory neurotoxicity. Methods Sixty-eight patients receiving oxaliplatin-based chemotherapy were randomly divided into treatment group(n=38, monosialoganglioside, 40 mg/d, 3d) and control group(n=30, fursultiamine, 50 mg, orally bid, three times a day, continuous medication) to prevent oxaliplatin-induced sensory neurotoxicity. The acute and cumulative sensory neurotoxicity, chemotherapeutic effect and adverse reactions in two groups after chemotherapy were assessed. Results The incidence of acute sensory neurotoxicity in monosialoganglioside group was significantly lower than that in control group(5.3% vs. 26.7%, P=0.013). The incidence of cumulative sensory neurotoxicity in control group was 63.3%(19/30), with grade 1-2 in 15 cases, grade 3 in 3 cases and grade 4 in 1 case, signifi cantly higher than that 15.8%(6/38) in monosialoganglioside group, with grade 1-2 in 6 cases. There was no statistically signifi cant difference in chemotherapy-induced adverse reaction, ORR, DCR or mPFS between both groups. Conclusion Monosialoganglioside is an effective neuroprotectant against oxaliplatin-induced sensory neurotoxicity without infl uencing in chemotherapeutic effi cacy or chemotherapy-induced adverse reaction.
- Monosialoganglioside,
- Oxaliplatin,
- Sensory neurotoxicity

FullText(HTML)

References (10)

References

[1]	Cassidy J, Misset JL.Oxaliplatin related side effects: Characteristics and management[J]. Semin Oncol, 2002, 29(5 Suppl 15):11-20.
[2]	Lévi F, Misset JL, Brienza S, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer[J]. Cancer, 1992, 69(4):893-900.
[3]	Gamelin E,Gamelin L,Bassi L,et al. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures[J]. Semin Oncol, 2002, 29(5 Suppl 15):21-33.
[4]	Lehky TJ, Leonard GD, Wilson RH, et al. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy[J]. Muscle Nerce, 2004, 29(3):387-92.
[5]	Cavaletti G, Tredici G, Petruccioli MG, et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of rat[J]. Eur J Cancer, 2001, 37(18):2457-63.
[6]	Cavaletti G, Petruccioli MG, Marmiroli P, et al. Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the rat[J].Anticancer Res, 2002,22(6C):4199-204.
[7]	De Santis S, Pace A, Bove L, et al. Patients treated with antitumor drugs displaying neurological defi cits are characerized by a low circulating level of nerve growth factor[J]. Clin Cancer Res, 2000, 6( 1):90-5.
[8]	Hochster HS,Grothey A,Childs BH. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity[J]. J Clin Oncol, 20 07, 25(25): 4028-9.
[9]	Yin XH, Sun LM, Deng SH. Mechanism of action and clinical research progress of monosialoganglioside[J].Zhongguo Ji Ceng Yi Yao,2006,13(9):1567-9.[尹晓慧, 孙立明, 邓树海. 神经节苷脂作用机制及临床研究进展[J]. 中国基层医药,2006,13(9):1567-9.]
[10]	Ning N, Chen NH. Progress in the research of Ganglioside’ s biological activities[J]. Sheng Li Ke Xue Jin Zhan, 2009, 40 (1):24.[宁娜，陈乃宏. 神经节苷脂的生物学活性[J]. 生理科学进展,2009,40(1):24.]

[1]	TONG Jinlong, WANG Haiyu, TIAN Xiaoqiang, LI Ying, LU Shihui, YE Wei. Prognostic Value of Radiation-Induced Lymphopenia in Patients with Unresectable Primary Hepatocellular Carcinoma Receiving Radiotherapy[J]. Cancer Research on Prevention and Treatment, 2024, 51(12): 1007-1014. DOI: 10.3971/j.issn.1000-8578.2024.24.0096
[2]	WANG Runmei, YANG Hao, YU Rong, WANG Zhenfei, WU Yu, LI Hong, HU Yue. Prophylactic Dexamethasone on Pain Flare in Spine Metastasis Stereotactic Body Radiotherapy and Hypofractionated Radiotherapy[J]. Cancer Research on Prevention and Treatment, 2021, 48(12): 1096-1100. DOI: 10.3971/j.issn.1000-8578.2021.21.0298
[3]	LIN Jian, WANG Haibo, SHEN Feng. Advance in Therapeutic Targets of Intrahepatic Cholangiocarcinoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(3): 224-228. DOI: 10.3971/j.issn.1000-8578.2021.20.1248
[4]	XIAO Jincheng, GUO Leiming, KANG Xinxin, BAI Qiwen, ZHANG Junling, LI Jing. Comparison of Efficiency and Safety Between Radiofrequency Ablation and Stereotactic Body Radiotherapy on Primary Small Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2017, 44(12): 831-835. DOI: 10.3971/j.issn.1000-8578.2017.17.0613
[5]	ZHANG Jiangzhou, LONG Zhixiong. Microwave Ablation Combined with Stereotactic Radiotherapy for Primary and Recurrent Hepatocellular Carcinoma after Interventional Treatment[J]. Cancer Research on Prevention and Treatment, 2014, 41(06): 649-652. DOI: 10.3971/j.issn.1000-8578.2014.06.031
[6]	WU Weizhang, CHANG Dongshu, ZHU Fuhai, WANG Yong. Dose Distribution of Body Gamma Rays Radiotherapy for Multiple Pulmonary Metastatic Tumor[J]. Cancer Research on Prevention and Treatment, 2014, 41(04): 391-394. DOI: 10.3971/j.issn.1000-8578.2014.04.024
[7]	WANG Peng, PAN Mian-shun, HUANG Yong. Effecting Observation of Stereotactic Radiotherapy Combined with Chemotherapy for Postoperative Local Recurrent Rectal Cancer[J]. Cancer Research on Prevention and Treatment, 2006, 33(07): 524-526. DOI: 10.3971/j.issn.1000-8578.2282
[8]	ZHANG Xin-hua, LUO Ding-tai, YANG Zi-wan, et al, . Hepatic artery intubatton chemotherapy and radiotherapy alternately to treat primary liver cancer[J]. Cancer Research on Prevention and Treatment, 2002, 29(01): 73-74. DOI: 10.3971/j.issn.1000-8578.134
[9]	XIAO Hong, PANG Xue-li, TAN Chong-fu, et al, . Preliminary Clinical Study of the Effect of Stereotactic Radiotherapy Boost Following Conventional Radiotherapy on Local Control Rate of Primary Nasopharyngeal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2001, 28(05): 405-406. DOI: 10.3971/j.issn.1000-8578.958
[10]	WANG Ying-xuan, PAN Long-sheng, ZHANG Ji, et al, . Stereotactic Radiosurgery for Pituitary Tumors[J]. Cancer Research on Prevention and Treatment, 2001, 28(02): 138-141. DOI: 10.3971/j.issn.1000-8578.2603

Cited By

Get Citation

PDF

XML

Article views (1435) PDF downloads (993)

Turn off MathJax

Article Contents

Abstract

References

Protective Effects of Monosialoganglioside on Oxaliplatin-induced Chronic Sensory Neurotoxicity

Abstract

References

Related Articles

Catalog

Download Center

Links

Contact Us

Protective Effects of Monosialoganglioside on Oxaliplatin-induced Chronic Sensory Neurotoxicity

Abstract

References

Related Articles

Catalog

Download Center

Links

Contact Us

Export File

Citation

Format

Content